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Abstract
Background—The major morbidity of hemophilia is bleeding induced hemophilic arthropathy
(HA) which once established may not be interrupted completely even by prophylactic clotting
factor replacement. Specific therapies to oppose inflammatory cytokines, including Interleukin 6
(IL-6) receptor antagonists, have become important in the management of inflammatory
arthritides.
Objectives—We investigated combining therapy using MR16-1, a rat IgG antibody directed
against mouse IL-6 receptor (anti-IL-6R), with factor VIII (FVIII) replacement to protect against
bleeding induced arthropathy in hemophilia A mice.
Methods—Three recurrent hemarthroses were induced in the knee joint capsule of factor VIII
knockout mice. Treatment at the time of each hemorrhage included either: No treatment; FVIII
replacement given at the time of hemorrhage; FVIII replacement at hemorrhage plus anti-IL-6R as
four weekly injections; FVIII replacement with non-specific control antibody (rat IgG); anti-IL-6R
alone without FVIII replacement. Six weeks following the first hemarthosis joints were harvested
and histopathology was scored for synovitis, for cartilage integrity and for macrophage
infiltration.
Results—Animals that received anti-IL-6R as an adjunct to FVIII replacement demonstrated the
best survival and the least acute joint swelling and pathology on histologic examination of
synovium and cartilage (P<0.05 for each parameter). All histopathologic parameters in the mice
receiving FVIII+anti-IL-6R were limited and were comparable to findings in injured
hemostatically normal mice. The major benefits of adjunctive anti-IL-6R were decreasing synovial
hyperplasia, hemosiderin deposition and macrophage infiltration.
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Conclusions—Short-course specific inhibition of inflammatory cytokines as an adjunct to
replacement hemostasis may be an approach to minimize hemophilic joint degeneration.
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Introduction
Hemophilia is an inherited bleeding disorder that results from deficient activity of blood
clotting factor VIII (hemophilia A) or factor IX (hemophilia B) [1]. The major disease-
related morbidity of hemophilia is hemophilic arthropathy (HA), a progressive destruction
of joints that results from recurrent bleeding into the joint space [1, 2]. Pathological changes
involving synovial hyperplasia, infiltration and proliferation of inflammatory cells,
neoangiogenesis, and osteochondral destruction are its hallmarks. Extravasation of blood
components into the joint space, in particular erythrocyte-derived heme iron and monocytes/
macrophages, induces arthritis with both inflammatory and degenerative features [3].
Monocytes/macrophages recruited to the area along with accompanying inflammatory
cytokines interleukin 6 (IL-6), interleukin 1(IL-1), tumor necrosis factor-alpha (TNF- α)
increase inflammatory response in the joints [3, 4]. The hyperplastic synovium is at risk for
recurrent cycles of target joint hemorrhage [5, 6].
Standard treatment of bleeding episodes is intravenous replacement of the deficient clotting
factor. Prompt, early treatment with adequate dosage of clotting factor concentrate can
effectively halt hemorrhage. Nevertheless, even without recurrent bleeding into the joint
space, inflammatory processes are incited by intraarticular blood that continue degenerative
changes for weeks following a bleeding episode; the inflammatory component of the disease
may become chronically present [3, 5, 7, 8]. Once HA is established, the pathologic changes
to cartilage and bone are irreversible [3]. Prophylaxis with clotting factor replacement
starting at a young age may decrease the frequency of joint hemorrhage and the incidence of
joint damage. However, recurrent/break-through joint bleeding and the possibility of
degeneration of HA persist in some patients despite preventive prophylactic replacement [9–
11]. Innovative therapies that can be used as an adjunct to clotting factor replacement to
prevent this common and serious complication could play an important role.
IL-6 is a multifunctional cytokine that possesses several proinflammatory properties. It is
central in the pathogenesis of several arthritis models [12, 13]. In rheumatoid arthritis (RA),
IL-6 promotes synovitis by inducing neovascularization, infiltration of inflammatory cells,
and synovial hyperplasia [14, 15]. It augments osteoclast formation and stimulates the
production of matrix metalloproteinases (MMPs) resulting in degeneration of bone and
cartilage [15]. IL-6, along with several cytokines and inflammatory mediators, including
TNF-α, interferon-gamma (IFN-γ), vascular endothelial growth factor (VEGF), IL-1β,
monocyte chemotactic protein-1 (MCP-1) have been implicated in blood-induced joint
damage in hemophilia [4, 16]. Moreover, the production of IL-6 is significantly increased in
synovium of HA patients [8].
MR16-1, a rat anti-mouse IL-6 receptor (anti-IL-6R) that blocks the IL-6 signaling pathway,
has proved effective in decreasing inflammatory changes in mouse models of many
autoimmune and inflammatory diseases [13, 17–19]. Preclinical efficacy of anti-IL-6R
approaches led to the development of Tocilizumab (TCZ), a humanized anti-human IL-6R,
which is presently used in RA patients and other inflammatory diseases [20]. However, the
beneficial effects of opposing IL-6 have never been explored in hemophilia. This is the first
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report investigating combining hemostatic replacement factor with opposing inflammatory
cytokine (IL-6) to protect against bleeding induced arthropathy in hemophilia A.
Materials and Methods
Mice
Eight- to fourteen-week-old factor VIII knock-out (FVIII −/−) mice generated by gene
targeting (E16 FVIII B6;129S4-F8tm1kaz) were originally supplied by Dr. H. H. Kazazian Jr.
(University of Pennsylvania, PA, USA) [21] and bred in house. Ten- to twelve-week-old
C57BL/6J wild-type (WT) mice were purchased from Jackson Labs (Bar Harbor, ME). All
investigations were performed in accordance with a protocol approved by the Institutional
Animal Care and Use Committee of the University of North Carolina at Chapel Hill. Mice
were anesthetized using Isoflurane/O2 for all procedures. All blood samples were collected
from the retro-orbital plexus into 1:9 parts 3.2% citrated sodium, centrifuged to obtain
platelet-poor plasma, and the plasma was stored at −80°C.
Treatment antibodies
MR16-1, rat anti-mouse IL-6R monoclonal IgG1 antibody, was a gift from Chugai
Pharmaceutical (Tokyo, Japan). The characteristics of this antibody have been previously
reported. [18, 22] Control IgG (purified from the serum of nonimmunized rats) was
purchased from Jackson ImmunoResearch (West Grove, PA,). Dosage and regimen were
chosen based on previous data generated in various mouse models by Mihara M et al. [13,
17].
Induction and treatment of recurrent hemarthrosis
Although the histopathologic features that develop within the hemophilic mouse joint
following exposure to blood closely resemble those seen in human hemarthropathy, the
FVIII −/− mice rarely bleed spontaneously in the joints [23]. Recurrent hemarthroses were
produced by three sequential induced joint hemorrhages. Intra-articular hemorrhage was
induced as previously described [24–26] by introducing a 30.5 gauge needle into the left
knee joint capsule through the infra-patellar ligament; although not relevant therapeutically,
5 microliters of normal saline was introduced to maintain parameters identical to our
previous report using this model [26]. Joint hemorrhages were induced on days 0, 7 and 14
to emulate recurrent hemarthrosis.
The dosage of FVIII treatment was selected based on a preliminary study demonstrating that
plasma from FVIII knockout mice that receive a dose of human recombinant factor VIII 150
U kg−1 (Advate™; Baxter Bioscience, Deerfield, IL) via the retroorbital venous plexus has
the same clotting time in seconds as does plasma from hemostatically normal wild type mice
in an aPTT assay. Specifically, platelet poor plasma from 12 hemostatically normal WT
mice was added to an equal volume aPTT reagent (Diagnostica Stago) and incubated for 3
minutes at 37 degrees C. Calcium chloride was then added and the time to form a clot was
assayed on a ST-4 Coagulation Analyzer (Diagnostica Stago, Asniéres, France) and the time
to clot was 32 seconds (range 31 to 33 seconds). We then injected separate groups of FVIII
−/− mice with a variety of doses of factor VIII and collected plasma at 15 minutes after the
dose to screen the clotting potential. The group of mice (N= 10) that received 150 IU/kg of
human FVIII demonstrated a median clotting time in the aPTT assay of 30.9 seconds (range
26 seconds to 33 seconds). Additional hemophilic mice that received 150 U kg−1 FVIII as a
preventive dose preceding needle injury survived the challenge with no significant joint
swelling during 2 days follow-up (n=10). Of note, it has been previously shown that the
circulating survival (half-life) of human factor VIII (Advate) is shorter in mice than in
humans [27].
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Treatments of FVIII −/− mice were assigned to 5 groups (Supplementary Fig. S1); Group 1)
No Rx: No treatment after each injury; Group 2) FVIII alone: recombinant FVIII following
induction of each injury; Group 3) FVIII + anti-IL-6R: FVIII following each injury and
MR16-1 intraperitoneally 8 mg after 1st injury, 0.5 mg after 2nd, 3rd injury and 7 days after
3rd injury; Group 4) FVIII+control IgG: FVIII following each injury and intraperitoneal
control IgG given intraperitoneally at the same dose and schedule as used for MR16-1;
Group 5) Anti-IL-6R alone: mice received only MR16-1 without FVIII replacement. To
simulate prompt “on demand” approach to clotting factor replacement, FVIII concentrate
was given 2 minutes after bleeding was induced. MR 16-1 and control IgG were given
immediately following FVIII. Treatment groups included equal numbers of male and female
mice. The mean ages were equivalent for mice in each study group, varying from 10.6 ± 1.8
weeks in the FVIII + control IgG group to 11.2 ± 1.8 weeks in the Anti-Il-6R group at the
time of the first injury. Groups were also balanced for mean weight, ranging from 23.2 ± 1.7
grams in the FVIII + anti-IL-6R group to 24.6 ± 1.6 grams in the FVIII alone group; doses
of all drugs were calculated based on the weight of the individual mouse and not on mean
weights of the study cohort.
Multiplex cytokine analysis
Peripheral blood was collected prior to injury and day 7. Plasma IL-1β, IL-6, interleukin 10
(IL-10), interleukin 17 (IL-17), TNF-α, MCP-1, vascular endothelial growth factor (VEGF),
interleukin 4 (IL-4), IFN-γ concentration were measured on a Bio-Plex 200 system (Bio-
Rad, Hercules, CA) using FMAP reagents from R&D Systems (Minneapolis, MN)
according to manufacturer’s instructions. Curve-fitting for primary data concentration
reporting was performed with the onboard Bio-Plex Manager v.5.0 software.
Joint diameter measurements
The diameters of the left knee joints were measured serially throughout the experiment. The
measurements were performed using a digital caliper (Mitutoyu 547- 301, Kanagawa, Japan)
from lateral to medial across the knee as previously described [25]. The diameter prior to the
induction of first hemarthrosis was used as baseline to calculate the percentage change in
joint diameter at later time points.
Histopathologic evaluation (Table S1)
Joint tissues were harvested on day 42. The knee joints were collected by sectioning the
femur and tibia 1-cm from the joint, fixed, and decalcified using routine histological
procedures [26]. The tissues were stained with hematoxylin and eosin (H&E) and Safranin-
O. Histopathologic grading for synovitis used the previously validated murine hemophilic
synovitis system of Valentino and Hakobyan [28]. Cartilage pathology was graded using the
Modified Mankin’s score [29, 30]. At least three representative fields from an equatorial
section of each knee were scored by two or more reviewers who were blinded to the
experimental conditions and scores from each joint were averaged. The sum of the average
synovitis and cartilage scores was calculated as the Global Score to represent the spectrum
of bleeding-induced joint pathology. Macrophages were identified by immunostaining for
CD68 with a rat anti-mouse F4/80 (Serotec, Raleigh, NC) at a 1:50 dilution, followed by
biotinylated anti-rat IgG (Vector Labs, Burlingame, CA) at a 1:100 dilution, and scored for
macrophage infiltration using Hoffman’s macrophage score, as previously described [31].
Narkbunnam et al. Page 4













Anti-human FVIII Bethesda inhibitor assay
Plasma for FVIII Bethesda inhibitor antibody was evaluated in all FVIII treated groups on
day 14 and 42 (prior to the 3rd injury and the day of sacrifice) using a START 4 Coagulation
Analyzer, as previously described [32].
Statistical analysis
Data are expressed as mean ± SD for continuous variables and proportions for categorical
variables. Differences between groups in continuous variables were examined for statistical
significance using the Man-Whitney U test, while differences in proportions were examined
by chi-square tests. Log-rank tests were used for overall comparison. Joint swelling in the
percentage change of the diameters was compared using a generalized estimating equation
(GEE) that counts dependence between outcomes in different follow-up times. P values less
than 0.05 were considered significant. All of the analyses were conducted by IBM SPSS
Statistics 19 (SPSS Inc., Chicago, IL) and SAS 9.2 (SAS Institute Inc., Cary, NC).
Results
Recurrent hemarthrosis were produced by three sequential induced joint hemorrhages. The
repeated severe hemarthrosis resulted in a survival of 35% in untreated hemophilic mice,
although hemostatically normal mice all survived. (Table 1) Treatment with anti-IL-6R
alone (without hemostatic support) did not improve the survival (P=0.492, log rank test).
Relative to the no treatment group, hemostatic support with FVIII significantly improved
survival (P<0.01) to 88%. The addition of anti-IL-6R with FVIII normalized survival.
MR16-1 interference with IL-6 receptor increases circulating plasma IL-6
A panel of plasma cytokines were measured prior to injury and at day 7 prior to the second
injury. Plasma from 16 uninjured and untreated FVIII −/− mice demonstrated a baseline
circulating IL-6 level of 5.6 pg/ml. Hemophilic mice surviving a single induced
hemarthrosis had significant elevations of plasma IL-6 at day 7 (to 88.4 ± 22.6 pg ml−1).
This elevation was partially corrected if mice received FVIII replacement at the time of
injury. (Fig. 1) The highest IL-6 levels were seen in mice treated with MR16-1, reflecting
the action of the antibody to block the physiologic clearance of IL-6 via interaction with
IL-6 receptor [33]. Compared to levels prior to hemarthrosis, there were no measurable
differences at day 7 for any other cytokines evaluated, including IL-4, VEGF, and TNF-α
(data not shown).
FVIII inhibitor formation
The E16 FVIII knockout mice reliably form neutralizing alloantibodies (inhibitors)
following exposure to the xenoprotein human FVIII [23]. After two doses of recombinant
human FVIII concentrate, one third of mice developed low titer FVIII inhibitors (less than 5
Bethesda Units) by day 14, regardless of treatment group. Following the three FVIII
treatment doses essentially all mice developed high titer circulating inhibitors measured at
the day 42 sacrifice (Table 2).
Combined FVIII and anti-IL-6R therapy minimizes joint swelling following hemarthrosis
Hemostatically normal WT mice exhibited no measurable joint swelling at any time point
(Fig. 2a). All hemophilic mice, regardless of treatment, developed markedly increased joint
diameter after a single hemarthrosis, with the exception of mice that received both FVIII and
anti-IL-6R. Following two hemorrhages, adjunctive anti-cytokine therapy with hemostatic
support significantly prevented swelling when compared to FVIII support alone (P<0.001
versus FVIII alone, estimated by GEE method); 14/15 animals in the adjunctive therapy
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group had no measurable swelling following two hemorrhages. By the time of the day 14
hemarthrosis, 5/15 mice in the FVIII + anti-IL-6R group developed inhibitors and the
response to the induced hemarthrosis was different for this subset of mice in that the third
joint injury (induced following inhibitor development) was associated with marked swelling.
The subset of mice that received adjunctive anti-cytokine therapy with FVIII and remained
free of inhibitors at day 14 (10/15 mice) had no significant increase in joint diameter (Fig.
2b).
Adjunctive anti-IL-6R therapy reduces pathological sequelae of bleeding induced
arthropathy on both synovium and cartilage
Following recurrent hemarthroses, all untreated hemophilia A mice that survived the
bleeding challenges developed severe synovitis, as evaluated at six week following the first
hemorrhage (Fig. 3a, 3b). The inter-reader correlation on the scoring of histopathology was
good (R2 > 0.96). The average score for synovitis was 7.6 ± 0.5 out of a maximum score of
10 in the Valentino grading system. Microscopic findings demonstrated obvious
proliferation of the synovial lining cells and subsynovial neoangiogenesis along with
hemosiderin staining and synovial villous formation. (Fig. 3c) Pits and erosions of the
articular cartilage surface were present in some mice. The measured changes in pathology
score for cartilage were considerably smaller than those for the synovitis score; the average
elevation in Mankin’s score for cartilage was 1.6 ± 0.6 and the average global score for
whole joint evaluation was 9.1 ± 0.9. Treatment with FVIII replacement reduced the degree
of synovitis. However, the pathological changes were still significantly different from the
pathology in normal hemostatic mice (P<0.05). The Mankin’s score associated with FVIII
treatment compared to no treatment was not statistically significant. We found no statistical
difference in any histological parameters between FVIII alone and FVIII+control IgG,
indicating that there was no protection from the development of pathologc outcome resulting
from a non-specific action of IgG.
Despite equivalent rates of inhibitor formation between groups, combined therapy using
FVIII+ anti-IL-6R significantly reduced pathological changes after hemarthrosis compared
with treatment with FVIII alone. The average synovitis score, Mankin’s score and Global
score were significantly lower: 2.67 ± 0.65, 0.27 ± 0.15 and 2.93 ± 0.68 respectively, for the
combined therapy compared to 5.27 ± 0.71, 1.80 ± 0.68 and 7.07 ± 1.22 respectively, for the
FVIII treatment alone (P<0.05). (Fig. 3b) All histological scores of FVIII+ anti-IL-6R group
were comparable to hemostatically normal mice. Five of fifteen mice (33.3%) exhibited no
sequelae at all on synovium (Valentino’s synovial score 0). The major effects of adjunctive
anti-IL-6R therapy on synovium were decreasing synovial hyperplasia and diminishing
hemosiderin deposition (P<0.05 versus FVIII alone) (Fig. 3c). Adjunctive anti-IL-6R
therapy was associated with a significantly lower risk of cartilage pathology (OR=0.17
95%CI 0.03–0.85, P=0.032).
Another major effect of adjunctive anti-IL-6R therapy was reduced macrophage
accumulation in synovium at the time of sacrifice (six weeks after first hemarthrosis). As
shown in figure 4, CD68 staining demonstrated the lowest average macrophage score
following combined therapy. There was no significant difference between the macrophage
score of FVIII+anti-IL-6R and hemostatically normal mice. (P=0.43)
Thirty to forty percent of mice in each treatment group that included human Factor VIII
therapy developed inhibitors that were measurable immediately prior to the third joint
hemorrhage; these mice would be expected to have impaired hemostatic potential of the
infused FVIII, and so a separate analysis was performed to explore the influence of FVIII
inhibitor antibody formation to the treatment outcomes. Regardless of whether an inhibitor
was present or not, the mice that received FVIII alone or received FVIII with non-specific
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IgG developed a similar degree of synovitis (Fig. 3d), as did the mice that received FVIII
plus anti-IL-6R but had Bethesda inhibitors. None of these groups of mice could be
considered to have the benefit of restoration of hemostasis with inhibition of inflammatory
cytokine. Only the subset that were free of factor VIII inhibitors and so could benefit from
combined therapy FVIII with anti-IL-6R were protected from the development of synovitis.
Almost no pathological changes were demonstrated; discoloration with hemosiderin was
observed in only one mouse, and the average synovitis score, Mankin’s score and Global
score were limited to 1.6 ± 0.72, 0.1 ± 0.1 and 1.7 ± 0.7 respectively. The pathological
outcomes of the subset that benefitted from unimpaired FVIII replacement with adjunctive
anti-cytokine therapy were equivalent to the outcome in non-hemophilic mice.
Discussion
The current study examines the hypothesis that the hemophilic joint that is exposed to
recurrent hemorrhage will be optimally protected if, in addition to hemostatic therapy,
specific adjunctive therapy is added that opposes inflammation. The hemophilic arthropathy
that develops following exposure of the joints to blood has histopathologic features that
resemble both inflammatory arthritis (e.g. rheumatoid arthritis) and degenerative arthritis
(e.g. osteoarthritis). Upregulation of inflammatory cytokines as a hallmark of synovitis is
exhibited in both hemophilic arthritis and rheumatoid arthritis [4]. In vitro studies have
demonstrated comparable increases of catabolic cytokines such as IL-1, IL-6 and TNF-α in
synovial tissue from patients with hemophilia arthropathy and RA [4]. The standard
treatment of hemophilic synovitis addresses the congenital deficiency of clotting activity by
replacing coagulation factors in response to bleeding and/or prophylactically. Although there
is evidence that the synovitis in hemophilia is mediated by the action of inflammatory
cytokines [3, 4], the current study is the first to take a pharmacologic approach to
specifically oppose proinflammatory cytokine activity (IL-6 activity) as an adjunctive
therapy to complement hemostatic support.
IL-6 plays several crucial roles in pathogenesis of inflammatory arthritis [12, 34]. IL-6 is
secreted by a variety of cells, including T cells, B cells, monocytes, and fibroblasts and it
possesses several biological activities that include regulation of immune response,
inflammation, and hematopoiesis [12]. IL-6 exerts its biological activities through two
molecules, an IL-6-specific receptor (IL-6R) and a membrane-bound signal transducer,
gp130 [34]. When IL-6 binds to IL-6R (IL-6/IL-6R) and forms the complex with gp130,
intracellular signaling pathways are activated that result in the promotion of T cell
proliferation, B cells, megakaryocytes, macrophages differentiation and regulation of Th17/
Treg cells balance [12, 34, 35]. Anti-IL-6R agents (MR16-1 or TCZ) inhibit the binding of
IL-6 to IL-6R and thus block IL-6 intracellular signaling. The efficacy of TCZ to slow or
prevent progressive joint degeneration in inflammatory arthritis has been demonstrated in
multiple randomized clinical trials, in both adult and pediatric patients [36–39].
In the treatment of rheumatic spectrum disorders, cytokine inhibiting drugs are typically
used on a chronic basis, including drugs that oppose TNF-α, IL1-β, or IL-6, [38]. We
wished to examine the ability of short-course cytokine inhibition (without prolonged
suppression) to alter the degenerative course that follows recurrent joint hemorrhage (target
joint bleeding). Although factor VIII knockout mice are widely used in the study of
hemophilia A, spontaneous joint bleeding is not commonly observed in this strain. Several
groups have demonstrated, however, that if a bleeding episode is induced in the hemophilic
mouse joint, histopathologic changes develop in the mouse joint that closely mimic those
seen in human hemarthropathy [24–26, 40] and these changes are specifically associated
with exposure of the joint to hemorrhage because they are not seen following a single joint
capsule puncture in mice with normal clotting factor activity (wild type mice) [26].
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IL-6 measurements in the MR16-1 treated mice gave a clear demonstration that the
monoclonal antibody therapy had a biologic effect. Plasma IL-6 was higher in mice that
received MR16-1, which is the expected result. Physiologic IL-6 clearance is triggered when
IL-6 forms a complex with soluble IL-6R (IL-6/sIL-6R complex). MR16-1 competitively
binds sIL-6R and thus inhibits IL-6 clearance [33]. Joint hemorrhage (reflected by joint
swelling present throughout the first week after injury) resulted in increased plasma IL-6
levels, although the elevation was partly ameliorated by prompt factor VIII treatment. While
the principal purpose of the cytokine analysis was to document, as was demonstrated, the
measurable effect of MR16-1 upon IL-6, a panel of additional cytokines was measured at
day 7 after injury. No detectable effect of MR16-1 administration upon circulating levels of
other cytokines was measurable at that time point. It is likely that assaying at day 7 alone
does not provide an informative picture of cytokine changes following joint hemorrhage and
that assaying multiple timepoints would be required to develop a full profile of such events.
Although such a profile of changes is beyond the scope of these investigations, Sen and
colleagues have recently published just such an analysis of mRNA and cytokine protein
changes at time points ranging from 1 hour to 60 days following this induced hemarthrosis
challenge in hemophilic mice [40].
Hemostatic therapy, given promptly after bleeding, was required to avoid synovitis in this
hemophilic model – cytokine inhibition alone as therapy for recurrent joint hemorrhage was
associated with mortality, joint swelling and pathology that were no different from the
untreated animals. Although FVIII replacement at the dose of 150 U kg−1 effectively
rescued survival of the hemophilic mice, if anti-IL-6R was not administered, joint swelling
was detected from day 3 onward (Fig. 2a,). The protection from joint swelling did not
appear to result from enhanced initial hemostasis, i.e. by a smaller initial volume of
extravasated blood immediately distending the joint, but rather by opposing the
inflammatory response to hemorrhage. In separate studies performed in hemophilia B mice
we have observed that on day 3 following a single joint capsular puncture, the red blood
cells begin to disappear from the joint space; in contrast, synovial proliferation and
macrophage infiltration begin at this timepoint. (Junjiang Sun, unpublished observation). In
the current studies, only the combination of prompt hemostatic support and short-course
anti-cytokine therapy resulted in normalization of swelling (days 1–13, Figure 2), synovitis
pathology score (Figure 3b–d4a–c), and global score (Figure 3b) to values seen in non-
hemophilic joints. Moreover, combining anti-IL-6R with factor replacement did not
overcome the detrimental effect of inhibitor formation (Figures 2b, 3d). Mice with evidence
of initial protection by FVIII combined with anti-IL-6R but with subsequent evidence of
factor VIII neutralization by the time of the third injury were not protected from later joint
distention. The development of this complication in a subset of mice further supports the
conclusion that combination therapy is optimal, in that initial protection afforded by
combination therapy was lost when effective hemostasis was lost.
Parallels that support this conclusion have been observed in hemophilia B mice exposed to
the same joint bleeding challenge and treated with cytokine inhibition that targets TNF-α
instead of IL-6 [41]. We have observed that hemophilia B mice (but not hemostatically
normal mice) that receive three induced knee hemorrhages develop considerable synovitis
despite episodic replacement with factor IX at the time of bleeding. The development of
synovitis is much improved if a short course of TNF-α receptor blockade with Etanercept
(ten doses given over 20 days) is initiated with the first hemarthrosis or prior to the second
hemarthrosis. (Sun J, et al. manuscript submitted.) It is interesting to note that hemophilia B
mice that were exposed to factor IX (FIX) during active hemarthrosis developed inhibitors at
a low incidence that was eliminated in the groups receiving the combination of factor IX
replacement with the anti-cytokine Etanercept [41]. Given the established property of IL-6
as a regulator of the balance between IL-17-producing Th17 cells and regulatory T cells [19,
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35, 42], the current study recorded closely the development of factor VIII inhibitor
antibodies in the study groups. The overall incidence, the rate of development, and the
median titers of inhibitors did not differ between treatment groups, regardless of MR16-1
therapy. It must be acknowledged that human factor VIII is a strongly immunogenic
xenoprotein in E16 hemophilic mice [23]. This is only one of a number of significant
differences that complicates direct comparison of the results in the studies of Etanercept
+FIX compared to the anti-IL-6R + FVIII studies; other differences from the FVIII studies
include the significantly lower immunogenicity of human FIX in hemophilia B mice
(C57Bl/6 strain) [23], the longer half-life of FIX, and the greater penetration of FIX into the
joint space [43], where it may have local hemostatic action [26]. Nevertheless, the finding of
improved protection from synovitis by combining hemostatic support with inflammatory
cytokine inhibition in two different experimental systems supports further investigation of
this strategy.
The effects of blood exposure upon the hemophilic joint may affect all three components of
the joint: the synovium, the cartilage, and the subchondral bone. The cytokines IL-1 and
TNF-α are known to be key inflammatory mediators of hemophilic arthropathy [5, 44].
These same cytokines, along with IL-17, have been demonstrated to stimulate RA synovial
fibroblasts to produce large amounts of IL-6, and that IL-6 in turn stimulated further
proliferation of synovial fibroblastic cells in the presence of sIL-6R [14, 15]. Furthermore,
IL-6-sIL-6R trans-signaling is necessary to induce receptor activator of NF-κB ligand
(RANKL) expression in synovial cells by TNF-α and IL-17 [15]. The central role of NF-
κB-responsive inflammatory cytokine genes has recently been emphasized by other
investigators using the same experimental model of hemophilic arthropathy as used in this
study [40]. RANKL stimulates osteoclast activity, survival and bone resorption and
enhances the hypertrophic process of synovium [44], putting the cartilage at risk for direct
synovial invasion and replacement. Anti-IL-6R potentially may protect synovium, cartilage
and bone via the inhibition of these biological activities of IL-6 and concurrently blocking
the signaling of TNF-α, IL-1, and IL-17 that occurs through IL-6/sIL-6R. Of the
components of the global joint evaluation performed in this study, the greatest
improvements that were achieved by combining cytokine inhibition with hemostasis were in
the areas of diminished synovial proliferation, hemosiderin deposition, macrophage
infiltration, and to a lesser degree cartilage erosion. It is possible that if the global
arthropathy evaluation were performed at different time points other differences would be
seen. In particular, it is conceivable that if hemosiderin deposition within joints were heavy
then synovial inflammation, although held in check during the course of the acute therapy
with the anti-cytokine drug, might be stimulated to appear at later time points after
discontinuation of the anti-IL-6R. With this in mind it is interesting to note that hemosiderin
deposition was lower in the combined treatment group, so that the load of this potential
chronic irritant was diminished. It is not possible to speculate whether hemosiderin load was
decreased due to an effect upon the amount of acute hemorrhage, the amount of late
rebleeding, or the efficiency of macrophage/monocyte scavenging of hemosiderin deposits.
Reactive infiltrating macrophages and activated macrophage-like synoviocytes, via pro-
inflammatory cytokines including IL-1 and TNF-α, contribute to synovial and cartilage
destruction in hemophilic arthropathy and fuel subacute and chronic intraarticular
inflammation [5, 44]. It is worth noting that in another hemophilic mouse model of wound
healing in hemophilia, the residence of macrophages in a dermal wound in hemophilic mice
is greatly prolonged when compared to hemostatically normal mice receiving an identical
injury [31]. The examination in our study was done at a subacute/early chronic period
following recurrent hemarthroses, and if the hemophilic mice were not treated, abundant
resident macrophages were detected in the subsynium at that stage, but not seen in wounded
hemostatically normal mice. Combining anti-IL-6R with factor replacement therapy (but
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neither treatment alone) nearly normalized the degree and incidence of synovial macrophage
accumulation. IL-6 has been shown to contribute to the perpetuation of chronic
inflammation by augmenting continuous production of monocyte chemotactic protein-1
(MCP-1) from endothelial cells, mononuclear cells, and synovial cells [12, 34]. Ovlisen, et
al, using a mouse model nearly identical to the model used in this study, showed elevated
concentrations of IL-6 and monocyte chemotactic protein-1 (MCP-1) in the synovial fluid
following induced hemarthrosis [45]. These data suggest that IL-6 promotes the local
inflammatory reaction by amplifying inflammatory cell infiltration. Combined anti-IL-6R
and factor replacement may normalize the macrophage accumulation.
As has been recently reviewed [46], there is limited human clinical trial data on the use of
anti-inflammatory drugs (NSAID and corticosteroids) in combination with hemostasis for
hemophilia. Direct inhibition of cytokines including TNF-α, IL-1, and IL-6 has proved
efficacious in inflammatory arthritis that is resistant to other disease-modifying anti-
rheumatoid drugs (DMARDS). TCZ in particular has several practical advantages for the
type of short-term adjunctive treatment modeled in this study. Although previous experience
with MR16-1 in mice guided the choice of a weekly dosing schedule for this study, the
human analogue TCZ is dosed clinically on a monthly schedule (adults) or a twice monthly
schedule (children). Efficacy and safety have been established in large scale clinical trials in
inflammatory arthritis conducted in both adult and pediatric populations [36–39]. The factor
VIII treatment in our study modeled an on-demand approach to treating hemophilic joint
bleeding episodes and did not model the efficacy of regular prophylactic dosing of FVIII
(either given alone or in combination with anti-cytokine). Institution of FVIII prophylaxis in
the preschool years is the pediatric standard of care for prevention of hemarthropathy in
most resource-rich countries. There exists data on the long-term use (at least 12 weeks and
up to several years of therapy) in children as young as 2 years of age undergoing treatment
for juvenile idiopathic arthritis, with a favorable risk-benefit profile [37, 39]. Safety and
efficacy data in children less than 2 years old is not established. Clotting factor with
adjunctive anti-IL-6R given in much shorter courses than reported in these human trials may
deserve investigation for hemophilic children over 2 years of age who have breakthrough
bleeding during FVIII prophylaxis as well as those receiving on demand therapy.
Critical to the appropriate application of adjunctive therapy will be an improved
understanding of factors that distinguish which individuals (likely the majority of the severe
hemophilia population) are well protected by prophylactic factor replacement regimens and
at relatively low risk of rapid joint degeneration and which individuals are at increased risk
of early or rapid deterioration following hemarthroses, and thus may benefit from opposing
inflammation along with replacement of hemostasis. This distinction between these subsets
of patients was recently underscored by the prospectively generated results of the Joint
Outcome Study, in which some boys who reported multiple joint bleeding episodes
remained free of MRI evidence of disease, while others with minimal or no reported
hemarthroses nevertheless manifested synovial and osteochondral pathology [10]. Efforts to
define predictors that distinguish individuals at increased risk of hemophilic joint
deterioration are being pursued, including genetic markers or biomarkers of increased
arthritis risk. It is possible that variable expression of polymorphic cytokine genes are
among the underlying risk factors associated with joint deterioration, just as they have been
associated with increased inhibitor risk in hemophilia [47, 48].
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Figure 1. Plasma IL-6 levels are affected by intraarticular hemorrhage, hemostatic replacement
and IL-6 receptor inhibition
Plasma IL-6 increased significantly after injury. Plasma IL-6 was measured by multiplex
cytokine analysis on day 7 prior to the second induced hemarthrosis. Each column and
vertical line indicates mean and SD. Baseline plasma IL-6 levels in a group of uninjured
hemophilia A mice were 5.6 pg ml−1 prior to the first injury and increased to 88.4 ± 22.6 pg
ml−1 at day 7 if the mice received no treatment. Treatment with FVIII concentrate resulted
in less severe IL-6 elevations. The higher levels of IL-6 in the anti-IL-6R alone group
compared with no treatment and in the FVIII+anti-IL-6R group compared with FVIII alone
reflect the effect of anti-IL-6R to inhibit IL-6R mediated IL-6 clearance, with the effect of
increasing free plasma IL-6.
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Figure 2. Joint swelling following hemarthrosis is affected by treatment choice
Joint diameters were measured serially and reported as average percentage change in
diameter compared to pre-injury baseline in hemostatically normal mice (orange line) and in
hemophilic mice. On days 0, 7, and 14 measurements were collected immediately prior to
induced hemarthrosisis 2a) Mice that received adjunctive anti-IL-6R with FVIII therapy
(green dashed line) demonstrated less joint swelling than animals receiving either hemostatic
therapy or anti-cytokine therapy alone. 2b) The total group of mice that received adjunctive
anti-IL-6R + FVIII (green dashed line in Figure 2a and 2b) included a subset of mice with
measurable circulating FVIII inhibitor at the time of the third joint hemorrhage. The
swelling following hemarthrosis is shown separately for mice that were inhibitor positive on
day 14 (red line) and those that were free of inhibitors at the time of all joint hemorrhages
(inhibitor negative, blue line).
Narkbunnam et al. Page 15













Narkbunnam et al. Page 16













Figure 3. Pathological sequelae of bleeding induced arthropathy on synovium and cartilage and
effect of therapy
Histopathologic examination was performed at the time of sacrifice at six weeks following
the first hemarthrosis.
a) H&E staining of injured knees; Original magnification of upper images 40×; black boxes
indicate location of detail in corresponding lower image (200×). Black arrows indicate width
of synovial lining layer, normally <4 cell layers. Green arrows: neoangiogenesis. Black
asterixes: hemosiderin. Shown, Left to Right:WT) Wild type: no significant pathological
changes, no synovitis or minimal synovitis; No Treatment) Joint space filled with
proliferative, hemosiderin-stained, hypervascular synovium; FVIII alone) moderate
subsynovial thickening and neoangiogenesis; FVIII+anti IL-6R) no significant pathological
changes, no synovitis or minimal synovitis was observed.
b) Synovitis was scored using the Murine Hemophilic Synovitis grading system described
by Valentino and Hakobyan. Cartilage pathology was scored using the Modified Mankin’s
score. For each experimental animal these scores were summed to generate a Global
Hemophilic Arthropathy score and the mean score from all animals in a treatment group that
survived to day 42 is plotted (see also details in Supporting Table S1)
c) The individual defects that contribute to the composite Synovitis Grade are plotted for
each treatment approach. The major effects of adjunctive anti-IL-6R therapy on synovium
were reducing synovial hyperplasia and hemosiderin deposition. Each bar indicates mean
and SD.*=P<0.05 versus injured WT mice by Mann-Whitney U test. ‡=P<0.05 comparing
score in WT mice or FVIII+anti-IL-6R to FVIII therapy alone by Mann-Whitney U test
d) A subset of mice in each treatment group that included FVIII replacement demonstrated
measurable circulating factor VIII inhibitor by the time of the third induced hemarthrosis.
The synovitis graded at sacrifice (Valentino score) is plotted separately for the subsets of
mice receiving each treatment approach based upon the presence (dark grey bars) or absence
(light grey) of FVIII inhibitor at the time of the third joint hemorrhage. Each bar indicates
mean and SD. * = P<0.05 by Mann Whitney U test
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Figure 4. Macrophage accumulation in synovial tissues
a) Macrophage accumulation was evaluated by CD68 staining and scored using a 4-point
scale as described in “Material and Method”. Each column and vertical bar indicates mean
and SD. * = P<0.05 versus injured WT by Mann Whitney U test.
b) Immunohistochemical staining of CD68+ macrophages in subsynovial space (staining
brown) A) WT hemostatically normal (score 0); B), No treatment: multiple clusters/sheets of
CD68+ cells (score 4); C) FVIII alone: macrophages scattered/touching (score 1) D) FVIII
+antiIL-6R: No subsynovial macrophage accumulation (score 0)
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Table 1
Survival rate
Group N Survival (%) P
1 No treatment 20 7 (35) Reference
2 FVIII alone 17 15 (88.2) 0.001
3 FVIII + anti-IL-6R 15 15 (100) <0.001
4 FVIII + control IgG 10 9 (90) 0.008
5 Anti-IL-6R alone 20 8 (40) 0.492
6 Injured WT 10 10 (100) 0.002
Survival rate was evaluated on day 42 following the first injury. P values for significant difference compared to the “No treatment” group were
calculated using log-rank test.
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Table 2
FVIII inhibitor formation
Day 14 Day 42
Incidence Titer median (range) Incidence Titer median (range)
FVIII + anti-IL-6R 31.2% 1.85 (1.4–8) 93.75% 126 (4.12–928)
FVIII alone 29.4% 1.6 (1.05–3.1) 93.3% 98.7 (1.46–448)
FVIII + control IgG 33.3% 0.6 (0.4–1.75) 100% 120 (20.6–264)
HA control 44.4% 3.35 (0.97–6.2) 100% 105.6 (7.8–240)
FVIII inhibitor titers were reported in Bethesda Unit. There was no statistically significant difference among groups for either incidence or titer of
inhibitors. HA control = Hemophilia A mice that received retroorbital FVIII 150 U kg−1weekly × 3 without inducing hemarthrosis (n=9). The
nonparametric Mann-Whitney test was used to assess significance between groups.
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